Global Primary Ciliary Dyskinesia Market to Eyewitness Massive Growth by 2031 | Boehringer Ingelheim GmbH, Rotech Healthcare Inc.

Primary ciliary dskinesia is a rare condition which is also known as Kartagener syndrome or immotile ciliary syndrome. This condition leads to chronic respiratory tract infections or other related conditions, normally occur in internal organs of the human body. The major symptoms of this condition are caused by abnormal flagella and cilia. Normally flagella are microscopic, thread-like projections that stick out from the surface of cells.

They are found in the linings of the airway, the reproductive system, and other organs and tissues. In many cases, primary ciliary dyskinesia can caused by mutations in the genes which results in defective flagella or cilia that are unable to move or move abnormally. As flagella have many important functions within the body, defects in these structures part can cause diseased condition.

The major driving factor for primary ciliary dyskinesia market is rising prevalence of respiratory tract diseases like COPD and asthma. According to Centers for Disease Control and Prevention, it is estimated that between 6.7 million and 9.3 million adults worldwide suffer with respiratory problems along with 147,101 deaths occurred due to chronic lower respiratory diseases.

For detailed insights on enhancing your product footprint, request for a sample here –

It is predicted to be the third most death causing factor for primary ciliary dyskinesia disease. Thus, increasing prevalence of respiratory tract diseases will boost the growth of primary ciliary dyskinesia market.

The funding for respiratory tract diseases like COPD and asthma supports researchers to focus and increase research about pediatric and adult respiratory tract diseases, which can also drive to the growth of primary ciliary dyskinesia market.

Moreover, high cost of the current treatment and diagnosis methods along with lack of awareness about rare respiratory diseases such as primary ciliary dyskinesia is expected to restrain the growth of primary ciliary dyskinesia Market.

The global primary ciliary dyskinesia Market is segmented on the basis of Treatment, Diagnosis and End User.

On the basis of Treatment, Primary Ciliary Dyskinesia Market Segmentation into:

  • Drug Treatment
  • Erythromycin
  • Clarithromycin
  • Azithromycin
  • Others
  • Chemotherapy
  • Radiotherapy
  • Others

On the basis of Diagnosis, Primary Ciliary Dyskinesia Market Segmentation into:

  • Genetic Testing
  • Electron and video Microscopy
  • Others

To receive extensive list of important regions, ask for TOC here –

On the basis of End User, Primary Ciliary Dyskinesia Market Segmentation into:

  • Research Centers
  • Hospitals
  • Clinics
  • Others

The global primary ciliary dyskinesia is majorly dominated by the drug treatment among treatment segment. Among the drug treatment, clarithromycinis becoming more popular as they can be used to treat many different types of bacterial infections affecting the respiratory system and skin. Clarithromycin is also used together with other medicines to treat stomach ulcers caused by Helicobacter pylori.

Based on the diagnosis, electron and video microscopy is expected to dominate the market growth. These are the main methods to take a sample either from airway or nasal cavity to analyze the sample under a microscope.

Hospitals will generate largest revenue share in primary ciliary dyskinesia market as the hospitals use advanced technology medical devices for patient care and also instant care will be available with use of microscopy test to asthma or COPD patients.

COVID-19 which, originated in the city of Wuhan, Mainland China, has spread aggressively to evolve into a global pandemic involving more than 170 countries. This pandemic has affected lives across the economic, social and political sphere. Treating COVID 19 infected patients is the primary focus of doctors and physicians alike at the moment, as this infection has no available cure.

A breakthrough at this moment can increase the stock prices of primary ciliary dyskinesia manufacturers due to increase patient pool thereby driving the growth of primary ciliary dyskinesia market.

Pre-Book Right Now for Exclusive Analyst Support –

North America is projected to emerge as prominent market in the global primary ciliary dyskinesia market due to increasing prevalence of respiratory tract diseases along with updating technology for rare diseases diagnosis and treatment methods.

Europe is expected to hold prominent share in the global primary ciliary dyskinesia market throughout the study period due to encouraging government policies for research & development and healthcare professionals by various European countries such as France and Germany.

Asia Pacific is the fastest growing market owing to more number of developing nations such as India, china are encouraging the growth of the healthcare domain. Furthermore, increasing patient population from respiratory tract diseases in developing countries will directly increase the demand for various treatment methods and will boost the growth of the primary ciliary dyskinesia market.

Some of the major key players competing in the global Boehringer Ingelheim GmbH, Rotech Healthcare Inc., GlaxoSmithKline, Allied Healthcare Inc., Novartis AG, Hill-Rom Holdings Inc., Pfizer Inc., Medline Industries Inc., Ltd., Teva UK Limited Acare Technology Co., Teruma Medical Corporation, Greinier Bio One International GmBH and others.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.


US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Visit Our Website:

Back to top button